RxDoctor Payments Data

Edgar Wayne, MD

Infectious Disease · Mission Viejo, CANPI 1508026766

Payments from drug & device makers

$711in general payments, 2019–2025

Across 41 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$357
  • EMD Serono, Inc.$113
  • Viiv Healthcare Company$106
  • AbbVie$29
  • La Jolla Pharmaceutical Company$25
  • Astellas Pharma US Inc$22
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$711100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$711 in reported general payments places this provider in the 55th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$190,555
Medicare patients
245
Services billed
4,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr21$314,540
BiktarvyBictegrav/Emtricit/Tenofov Ala46$195,219
CresembaIsavuconazonium Sulfate28$139,693
TivicayDolutegravir Sodium47$102,249
PifeltroDoravirine28$49,785
TriumeqAbacavir/Dolutegravir/Lamivudi13$48,718
PrezcobixDarunavir/Cobicistat18$44,340
ErtapenemErtapenem Sodium113$36,702
DovatoDolutegravir Sodium/Lamivudine12$35,145
Posaconazole18$23,807
Fosfomycin Tromethamine116$19,608
Voriconazole56$19,434
Daptomycin48$19,215
Methenamine Hippurate206$12,891
Cefepime Hcl50$11,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$12$314,54021 claims
GileadBiktarvy$357$195,21946 claims
Viiv Healthcare CompanyTivicay, Triumeq, Dovato$106$186,11172 claims
Astellas Pharma US IncCresemba$22$139,69328 claims
MerckPifeltro$13$49,78528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 856 infectious disease providers in California.

Other infectious disease in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →